WO2005076819A2 - Chlorite in the treatment of neurodegenerative disease - Google Patents
Chlorite in the treatment of neurodegenerative disease Download PDFInfo
- Publication number
- WO2005076819A2 WO2005076819A2 PCT/US2005/002469 US2005002469W WO2005076819A2 WO 2005076819 A2 WO2005076819 A2 WO 2005076819A2 US 2005002469 W US2005002469 W US 2005002469W WO 2005076819 A2 WO2005076819 A2 WO 2005076819A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- als
- chlorite
- disease
- macrophage
- cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Definitions
- the present invention generally relates to the use of chlorite in treatment of neurodegenerative disease, particularly a neurodegenerative disease characterized by pathologic macrophages, such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), HIN-associated neurological disorders, or Alzheimer's disease (AD).
- ALS amyotrophic lateral sclerosis
- MS multiple sclerosis
- AD Alzheimer's disease
- Neurodegenerative diseases are generally characterized by a degeneration of neurons in either the brain or the nervous system of an individual.
- Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and multiple sclerosis (MS) fall within this category. These diseases are debilitating, the damage that they cause is often irreversible, and the outcome in a number of cases is fatal.
- ALS is characterized by gradual degeneration of motor neuron cells in the spinal cord and brain, which ultimately leads to progressive weakness and paralysis of muscle and death. ALS occurs in two clinically indistinguishable forms, referred to as a sporadic form and a familial form.
- the pathogenesis of ALS is incompletely understood, although different hypotheses have been suggested, including mitochondria dysfunction, mutation in the superoxide dismutase gene, and defects in neuronal glutamate transport. Autoimmunity has also been hypothesized to be involved in ALS pathogenesis (Appel et al. 1993. J Neurol Sci. 118:169-174).
- Retroviral infection has recently been implicated in the pathogenesis of an ALS-like syndrome in patients with HIV-associated disease. Moulignier et al. (Reversible ALS-like disorder in HIN infection. Neurology. 57:995-1001) recently reported the outcome of six HIN- 1 -infected patients with a neurologic disorder mimicking ALS and all those patients stabilized or improved with antiretroviral therapy. MacGrowen et al. (2001. An ALS-like syndrome with new HIN infection and complete response to antiretroviral therapy. Neurology. 57:1094-10) also reported a dramatic clinical response to antiretroviral therapy in an ALS-like syndrome with new HIN infection.
- HIN-associated dementia HID
- Macrophage activation has been reported in spinal cords of patients with ALS disease (Appel et al. 1993, supra; Engelthardt et al. 1990, supra; Obal et al. 2001, supra; McGeer et al. 2002, supra), although the role of macrophage activation in ALS pathogenesis has not been previously determined.
- AD Alzheimer's disease
- AD diagnosis is generally a diagnosis of "possible” or “probable” AD.
- doctors can diagnose AD correctly up to 90 percent of the time.
- tools are used to diagnose "probable” AD, including medical history, analysis of blood urine, or spinal fluid, to rule out other causes (e.g., thyroid deficiencies, infectious disease, etc.), brain scans, and neuropsychological tests to asses memory, problem solving, attention, counting, and language.
- MS Multiple sclerosis
- plaques areas of white matter of the central nervous system, known as plaques, become inflamed. Inflammation of these areas of plaque is followed by destruction of myelin, the fatty substance that forms a sheath or covering that insulates nerve cell fibers in the brain and spinal cord.
- myelin facilitates the smooth, high-speed transmission of electrochemical messages between the brain, spinal cord, and the rest of the body. Damage to the myelin sheath can slow or completely block the transmission of these electrochemical messages, which can result in diminished or lost bodily function.
- MS The most common course of MS manifests itself as a series of attacks, which are followed by either complete or partial remission, during which the symptoms lessen only to return at some later point in time. This type of MS is commonly referred to as “relapsing- remitting MS.”
- Another form of MS called “primary-progressive MS,” is characterized by a gradual decline into the disease state, with no distinct remissions and only temporary plateaus or minor relief from the symptoms.
- secondary-progressive MS starts as a relapsing-remitting course, but later deteriorates into a primary-progressive course of MS.
- the symptoms of MS can be mild or severe, acute or of a long duration, and may appear in various combinations. These symptoms can include vision problems such as blurred or double vision, red-green color distortion, or even blindness in one eye, muscle weakness in the extremities, coordination and balance problems, muscle spasticity, muscle fatigue, paresthesias, fleeting abnormal sensory feelings such as numbness, prickling, or "pins and needles" sensations, and in the worst cases, partial or complete paralysis. About half of the people suffering from MS also experience cognitive impairments, such as for example, poor concentration, attention, memory and/or judgment. These cognitive symptoms occur when lesions develop in those areas of the brain that are responsible for information processing.
- the invention features methods of treating a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS) in a subject by administering chlorite in an amount effective to decrease blood immune cell activation.
- a macrophage-associated neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), or multiple sclerosis (MS)
- ALS amyotrophic lateral sclerosis
- AD Alzheimer's disease
- MS multiple sclerosis
- the invention also features methods of monitoring therapy by assessing blood immune cell activation before and after therapy.
- Fig. 1 is a graph showing the relationship of the revised ALS Functional Rating Score
- ALSFRS-R to CD4 T-cell co-expression of the activation antigen CD38 in ALS patients.
- Patients with ALS were divided into two groups based on a score of 24, the midpoint of the ALSFRS-R scale.
- Figs. 2a- 2b are graphs showing analyses of macrophage activation defined by CD14 co-expression of HLA-DR in patients with ALS.
- Figs. 3a-3b are graphs showing a comparison of serum-IgG and -IgM levels between normal controls and ALS patient groups by ALSFRS-R categories.
- Fig. 3 a is a graph showing that significantly lower levels of serum-IgG were found in ALS patients with severe impairment compared to normal controls (P ⁇ 0.05), but with no difference between patients with milder impairment and normal controls.
- Fig. 3b is a graph showing levels of serum-IgM in patients with milder impairment were significantly higher than normal controls (P ⁇ 0.01), but with no difference between patients with severe impairment and normal controls.
- Fig. 4 is a graph showing the effects of WF10 administration upon activated blood macrophages in an ALS patient.
- Fig. 5 is a graph of a composite set of curves representing blood macrophage activation measurements taken from a patient with multiple sclerosis treated one cycle of WF10.
- Fig. 6 is a graph showing the results of administration of WF10 to two ALS patients
- the invention is based on the discovery that administration of WF10, which comprises chlorite (e.g., in the form of tetrachlorodecaoxygen (TCDO)) as its active ingredient, provides for treatment of patients having amyotrophic lateral sclerosis (ALS) and for treatment of patients having multiple sclerosis (MS).
- chlorite provides for a decrease in activated blood immune cells (e.g., activated macrophages), which are elevated in ALS and MS patients and contribute to ALS and MS disease pathogenesis.
- activated blood immune cells e.g., activated macrophages
- AD Alzheimer's disease
- the invention is thus applicable to treatment of neurodegenerative diseases associated with activated blood immune cells, particularly with proliferating or inappropriate activated macrophages.
- a "neurodegenerative disease” refers to a central nervous system characterized by progressive, normally gradual, loss of functional neural tissue. Of particular interest in the present invention is the treatment of neurodegenerative diseases in which that affected patient has activated blood immune cells, particularly with proliferating or inappropriate activated macrophages.
- Reference to a "non-diseased” individual generally means an individual who is not diagnosed as having, or is not suspected of having, the relevant neurodegenerative disease.
- Reference to a “diseased” individual generally means an individual who has been diagnosed as having, or who is suspected of having, the relevant neurodegenerative disease.
- Exemplary neurodegenerative diseases include amyotrophic lateral sclerosis, multiple sclerosis, and pathogen-mediated or pathogen-associated neural diseases or symptoms (such as viral infection, e.g., HIV infection).
- macrophage and “monocyte” are used interchangeably, as it is understood that in the art the term “monocyte” is often used to describe a circulating mononuclear cell that expresses the CD 14 cell surface marker, and when in a tissue this cell is also classified as a macrophage.
- abnormal macrophage or "activated circulating monocyte” or “activated monocyte” as used interchangeably herein denotes a monocyte which expresses CD14 (i.e., CD 14+) and which expresses an elevated level of HLA-DR, the major histocompatibility antigen class II, and/or which expresses CD 16 (i.e., CD 16+).
- CD14 i.e., CD 14+
- CD 16 i.e., CD 16+
- abnormal macrophages are found in peripheral blood but they may also be found in other biological samples from an individual. Generally, these abnormal macrophages are present without identifiable concomitant T cell activation in the ALS patients.
- detecting the "presence of abnormal macrophages” generally means detecting the level of abnormal macrophages.
- the level of abnormal macrophages (or activated monocytes) is indicated by the level of HLA-DR expression in a population of CD 14+ cells and/or the percentage of CD 16+ cells in a population of CD 14+ cells and/or the number of CD14+/CD16+ cells, although other markers that indicate monocyte activation, differentiation and/or proliferation could be used. It is understood that an absolute or even relative level need not be determined; an observation of detectable abnormal macrophages is sufficient.
- a "proliferating macrophage” or “promac” is understood in the art and as used herein denotes a disease-associated blood macrophage which exhibits an elevation in proliferation and/or activation markers relative to non-disease blood macrophages. Normally a macrophage is a terminally differentiated cell incapable of further division. For purposes of this invention, a “proliferating macrophage” is capable of further division or is in a portion of the cell cycle not considered to be terminal or end stage, and/or has undergone inappropriate activation (e.g., are "inappropriately activated",) or is undergoing inappropriate activation. Methods of detecting proliferating macrophage(s) are discussed below.
- Pathologic macrophages as used herein is meant to encompass both proliferating macrophages and inappropriately activated macrophages (e.g., abnormal macrophages). Pathologic macrophages thus encompass proliferating macrophages, as defined above, as well as macrophages in the blood that may not exhibit proliferation markers at any given time, but are nonetheless chronically activated, and thus are in a pathogenic state.
- detecting the "presence of proliferating macrophages" generally means detecting the level of proliferating macrophages. It is understood that an absolute or even relative level need not be determined; an observation of detectable proliferating macrophages is sufficient.
- a "macrophage-associated" disease, disorder or indication is a disease, disorder or indication that is associated with pathologic macrophages an elevated, or abnormal, level or rate of macrophage proliferation as compared to control sample(s).
- Such disorders include, but are not limited to, macrophage-associated neurodegenerative disorders, such as ALS, MS, HIV-associated neurological disorders, and AD.
- the terms “disorder” and “disease” are used interchangeably herein.
- An “HIV-associated” disease is defined more broadly as generally associated with or secondary to an HIV infection; “HIV-mediated” diseases, for example, are included in those considered to be “HIV-associated.”
- the disorder contemplated for treatment according to the invention is not cancer (e.g.,.
- the disorder contemplated for treatment according to the invention is not an autoimmune disease (e.g.,. the macrophage- associated is a disease or disorder other than an autoimmune disorder or disease).
- the disorder is not graft rejection (transplant rejection).
- the disorder treated is a viral infection, particularly an HIV or HCV infection (i.e., the patient is not virally infected, e.g.,.
- the disorder is not HIV-infected or HCV-infected)
- the disorder is not have HIV-associated dementia (e.g., , the patient does not have AIDS dementia),
- Macrophage-associated neurodegenerative disorder is specifically defined herein to exclude cancer, HIV infection, HCV infection, and autoimmune diseases.
- a "macrophage-associated neurodegenerative disorder” is a neurodegenerative disease in which the patient has pathologic macrophages (e.g., abnormally activated macrophages and/or proliferating macrophages, particularly a disease associated with an elevated, or abnormal, level or rate of macrophage proliferation as compared to control sample(s)).
- pathologic macrophages e.g., abnormally activated macrophages and/or proliferating macrophages, particularly a disease associated with an elevated, or abnormal, level or rate of macrophage proliferation as compared to control sample(s)
- Macrophage-associated neurodegenerative disorder is specifically defined herein to exclude cancer and autoimmune diseases.
- ALS Amyotrophic lateral sclerosis
- motor neurons motor neurons in the brain
- motor neurons in the spinal cord motor neurons in the spinal cord
- ALS includes all of the classifications of ALS known in the art, including, but not limited to classical ALS (typically affecting both lower and upper motor neurons), Primary Lateral Sclerosis (PLS, typically affecting only the upper motor neurons), Progressive Bulbar Palsy (PBP or Bulbar Onset, a version of ALS that typically begins with difficulties swallowing, chewing and speaking), Progressive Muscular Atrophy (PMA, typically affecting only the lower motor neurons) and familial ALS (a genetic version of ALS).
- classical ALS typically affecting both lower and upper motor neurons
- PPS Primary Lateral Sclerosis
- PBP or Bulbar Onset Progressive Bulbar Palsy
- PMA Progressive Muscular Atrophy
- familial ALS a genetic version of ALS
- MS Multiple sclerosis
- RRMS Relapsing-remitting
- SPMS Secondary progressive
- PPMS Primary progressive
- AD Alzheimer's disease
- DSM IV American Psychiatric Association
- An "individual” is a vertebrate, preferably a mammal, more preferably a human.
- Mammals include, but are not limited to, farm animals, sport animals, rodents, primates, and pets.
- a "macrophage-associated neurodegenerative disease individual” or a “macrophage-associated neurodegenerative disease patient” is an individual who is diagnosed as having a neurodegenerative disease or is suspected of having a neurodegenerative disease by demonstrating clinical symptoms of a neurodegenerative disease, which symptoms include pathologic macrophages in the patient's blood.
- a “non-macrophage-associated neurodegenerative disease individual” is an individual who is not diagnosed as having, and not suspected of having, a macrophage-associated neurodegenerative disease.
- Macrophage- associated neurodegenerative disorder is specifically defined herein to exclude cancer and autoimmune diseases.
- An "ALS individual” or an "ALS patient” is an individual who is diagnosed as having
- Non-ALS individual is an individual who is not diagnosed as having ALS or not suspected of having ALS. ALS and methods of diagnosing ALS are known in the art and are discussed herein.
- An "AD individual” or an “AD patient” is an individual who is diagnosed as having
- AD Alzheimer's disease
- a "non-AD individual” is an individual who is not diagnosed as having AD or not suspected of having AD.
- AD and methods of diagnosing AD are known in the art and are discussed herein.
- An "MS individual” or an “MS patient” is an individual who is diagnosed as having
- MS or is suspected of having MS by demonstrating MS-associated symptoms.
- a "non-MS individual” is an individual who is not diagnosed as having MS or not suspected of having MS. MS and methods of diagnosing MS are known in the art and are discussed herein.
- “Development” or “progression” of a disease e.g., a macrophage-associated neurodegenerative disease such as ALS, of AD, or of MS, herein means initial manifestations and/or ensuing progression of the disorder.
- a disease e.g., a macrophage-associated neurodegenerative disease such as ALS, of AD, or of MS
- development of ALS or of MS can be detectable and assessed using standard clinical techniques, such as nerve and muscle biopsy and CNS scanning technologies such as MRI.
- development also refers to disease progression that may be undetectable.
- development or progression refers to the biological course of the disease state.
- “Development” includes occurrence, recurrence, and onset.
- onset or "occurrence” of ALS, AD, or MS includes initial onset and/or recurrence.
- a macrophage-associated neurodegenerative disease a disease, such as ALS, AD or MS, means to defer, hinder, slow, retard, stabilize, and/or postpone development of one or more symptoms, of the disease, including decreasing the rate at which the patient's disease progresses (e.g., to shift the patient from rapidly progressing disease to a more slowly progressing disease).
- This delay can be of varying lengths of time, depending on the history of the disorder and/or the medical profile of the individual being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop detectable disease.
- a method that "delays" development of disease is a method that reduces the extent of the disease in a given time frame, when compared to not using the method. Such comparisons are typically based on clinical studies, using a statistically significant number of subjects, although this knowledge can be based upon anecdotal evidence. "Delaying development” can mean that the extent and/or undesirable clinical manifestations are lessened and/or time course of the progression is slowed or lengthened, as compared to not administering the agent. Thus the term also includes, but is not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, and remission (whether partial or total) whether detectable or undetectable.
- biological sample encompasses a variety of sample types obtained from an individual and can be used in a diagnostic or monitoring assay.
- the definition encompasses blood and other liquid samples of biological origin, solid tissue samples such as a biopsy specimen or tissue cultures or cells derived therefrom, and the progeny thereof.
- the definition also includes samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components, such as proteins or polynucleotides.
- biological sample encompasses a clinical sample, and also includes cells in culture, cell supematants, cell lysates, serum, plasma, biological fluid, and tissue samples.
- the sample will be, or be derived from, peripheral blood and as such is a "blood sample”.
- the blood will have been enriched for a macrophage fraction, by using, for example, glass or plastic adherence.
- a "blood sample” is a biological sample which is derived from blood, preferably peripheral (or circulating) blood.
- a blood sample may be, for example, whole blood, plasma or serum.
- an "effective amount" is an amount (of the agent) that produces a desired and/or beneficial result.
- An effective amount can be administered in one or more administrations.
- an effective amount is an amount sufficient to decrease the level of abnormal macrophages (pathologic macrophages) in a macrophage- associated neurodegenerative disease patient or derived from a macrophage-associated neurodegenerative disease individual.
- an effective amount is an amount sufficient to decrease the level of abnormal macrophages in an ALS patient or derived from an ALS individual.
- an effective amount is an amount sufficient to decrease the level of abnormal macrophages in an MS patient or derived from an MS individual.
- an effective amount is an amount sufficient to decrease the level of abnormal macrophages in an AD patient or derived from an AD individual.
- An "amount sufficient to decrease the level of abnormal macrophages" preferably is able to decrease the level of abnormal macrophages by at least about 25%, preferably at least about 50%, more preferably at least about 75%, and even more preferably at least about 90%. Such a decrease may have desirable concomitant effects, such as to palliate, ameliorate, stabilize, reverse, slow or delay progression of disease, delay and/or even prevent onset of disease.
- "amount sufficient to decrease the level of HLA-DR expression by CD 14+ cells” preferably is able to decrease the level of HLA-DR expression by at least about 25%, preferably at least about 50%, more preferably at least about 75%, and even more preferably at least about 90%. Such a decrease may have desirable concomitant effects, such as to palliate, ameliorate, stabilize, reverse, slow or delay progression of disease, delay and/or even prevent onset of disease.
- decreasing the "level of abnormal macrophages" generally means decreasing the population number of abnormal macrophages or activated monocytes and/or decreasing the level of HLA-DR expression in a population of CD 14+ cells.
- the level of abnormal macrophages can be assayed by determining the percentage of CD 16+ cells in a population of CD 14+ cells and/or the number of CD14+/CD16+ cells in the biological sample. It is understood that an absolute level need not be determined; an observation of a relative level of abnormal macrophages is sufficient.
- Modulating macrophage proliferation means that the level or rate of proliferation is altered when compared to not administering an agent that changes macrophage proliferation.
- modulating macrophage proliferation through use of chlorite -containing composition means that the level of proliferating macrophages or the rate of proliferation is altered when compared to not administering the agent.
- modulating macrophage proliferation means a change in the level of proliferating macrophages or the rate of macrophage proliferation of at least 25%, preferably at least 50%, more preferably at least 75%, and even more preferably at least 90%.
- modulating macrophage proliferation means that the level of proliferating macrophages or the rate of proliferation is decreased when compared to the same parameter in that individual when no agent is administered. However, during the course of therapy, for example, it may be desirable to increase the level of proliferating macrophages or the rate of proliferation from a previously measured level. The degree of modulation may be assessed by measurement of macrophage proliferation, which will be discussed below, and generally entails detecting a proliferation marker(s) in a macrophage population or uptake of certain substances such as BrdU or 3H-thymidine (which would provide a quantitative measure of proliferation).
- Treatment means any therapeutic intervention in a subject, usually a mammalian subject, generally a human subject, including: (i) prevention, that is, causing overt clinical symptoms not to develop, e.g., preventing disease progression to a harmful state; (ii) inhibition, that is, arresting the development or further development of clinical symptoms, e.g., mitigating existing clinical symptoms; and/or (iii) relief, that is, causing the regression of clinical symptoms, e.g., causing relief from clinical symptoms.
- Exemplary clinical symptoms of ALS include muscle weakness, muscle wasting, muscle cramping, muscle twitching, slurred or slow speech, difficulty swallowing, and slow, uncoordinated movements.
- Further exemplary clinical symptoms of ALS include those detectable in a biological sample obtained from a subject having or suspected of having ALS, e.g., increased CD4:CD8 cell ratio compared to normal, decreased number of CD14+ cells compared to normal, increased expression of HLA-DR on CD 14+ cells compared to normal CD 14+ cells, increased levels of activated monocytes or macrophages compared to normal, the presence of proliferating macrophages, and decreased serum IgG and/or IgM compared to normal, where "normal” as used herein means a subject unaffected by ALS or cells from such an unaffected subject.
- Treating thus encompasses achieving a decrease in one or more clinical symptoms, which decrease may have desirable concomitant effects, such as to palliate, ameliorate, stabilize, reverse, slow or delay progression of disease, delay and/or even prevent onset of disease.
- Exemplary clinical symptoms of AD include mild forgetfulness, including trouble remembering recent events, activities, or the names of familiar people or things; difficulty in solving simple math problems; trouble remembering how to do simple tasks (e.g., brushing teeth or combing hair); inability to think clearly; difficulty spekaing, understanding, reading, or writing; and anxiety or aggressivness, or tendency to wander away from home.
- MS lassitude also referred to as MS lassitude
- muscle fatigue also referred to as MS lassitude
- paresthesias difficulty in walking and/or balance problems
- abnormal sensations such as numbness, prickling, or "pins and needles”
- pain, bladder dysfunction, bowel dysfunction changes in cognitive function (including problems with memory, attention, concentration, judgment, and problem-solving), dizziness and vertigo, emotional problems
- Severe cases can involve partial or complete paralysis, (such as blurred or double vision, red-green color distortion, or even blindness in one eye).
- Other symptoms include headache, hearing loss, itching, seizures, spasticity, speech and swallowing disorders, and tremors.
- MS further exemplary clinical symptoms of MS include those detectable in a biological sample obtained from a subject having or suspected of having MS, e.g., increased CD4:CD8 cell ratio compared to normal, decreased number of CD 14+ cells compared to normal, increased expression of HLA-DR on CD 14+ cells compared to normal CD 14+ cells, increased levels of activated monocytes or macrophages compared to normal, the presence of proliferating macrophages, and decreased serum IgG and/or IgM compared to normal, where "normal” as used herein means a subject unaffected by MS or cells from such an unaffected subject.
- Treating thus encompasses achieving a decrease in one or more clinical symptoms, which decrease may have desirable concomitant effects, such as to palliate, ameliorate, stabilize, reverse, slow or delay progression of disease, delay and/or even prevent onset of disease.
- subject and patient mean a member or members of any mammalian or non-mammalian species that may have a need for the pharmaceutical methods, compositions and treatments described herein.
- Subjects and patients thus include, without limitation, primate (including humans), canine, feline, ungulate (e.g., equine, bovine, swine (e.g., pig)), avian, and other subjects.
- primate including humans
- canine feline
- ungulate e.g., equine, bovine, swine (e.g., pig)
- avian avian
- Humans and non-human animals having commercial importance are of particular interest.
- mammalian means a member or members of any mammalian species, and includes, by way of example, canines; felines; equines; bovines; ovines; rodentia, etc. and primates, particularly humans.
- Non-human animal models, particularly mammals, e.g. primate, murine, lagomorpha, etc. may be used for experimental investigations.
- unit dosage form refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of compounds of the present invention calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable excipient (e.g., pharmaceutically acceptable diluent, carrier or vehicle).
- a pharmaceutically acceptable excipient e.g., pharmaceutically acceptable diluent, carrier or vehicle.
- a "pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes an excipient that is acceptable for veterinary use as well as human pharmaceutical use.
- “A pharmaceutically acceptable excipient” as used in the specification and claims includes both one and more than one such excipient.
- the source of chlorite ions for administration of chlorite according to the invention can be provided in a variety of forms.
- chlorite can be administered as a chlorite salt
- chlorite can be administered as a matrix of chlorite ions, e.g., described in U.S. Pat. No. 4,507,285.
- the chlorite ions are provided in a compositions having the general formula
- Such agents can have an O 2 band at 1562 cm “1 in the Raman spectrum and an O-O interval of 123 pm. Production of such agents is known in the art, see, e.g., U.S. Pat. No. 4,507,285.
- the method of treatment involves administration of an aqueous solution of a product known as "tetrachlorodecaoxygen anion complex", commonly abbreviated as "TCDO".
- TCDO tetrachlorodecaoxygen anion complex
- agents that provide a source of chlorite ions can be administered in a free base or free acid form (that is, as the free compound and not as a salt).
- any pharmaceutically acceptable salt(s) of the compound(s) can also be used.
- Pharmaceutically acceptable salts are those salts which retain the biological activity of the free compounds and which are not biologically or otherwise undesirable.
- stereoisomers of the compounds disclosed can also be used in the invention, including diastereomers and enantiomers, as well as mixtures of stereoisomers, including, but not limited to, racemic mixtures. Unless stereochemistry is explicitly indicated in a structure, the structure is intended to embrace all possible stereoisomers of the compound depicted.
- Chlorite can be provided in any suitable formulation, which can be selected according to the desired route of administration.
- U.S. Pat. No. 4,725, 437 describes an aqueous solution of a chemically stabilized chlorite matrix suitable for intravenous administration in a dosed amount of about 6.2 x 10 " 6 mole of ClO 2 " to 9.3 x 10 "5 mole of ClO 2 "" per kg of body weight in humans and non-human animals.
- the solution contains the chlorite matrix in a concentration of about 12 to 72 micromol of ClO 2 "" per ml. Further chlorite fonnulations are described in U.S. Pat. Nos. 4,507,285 and 4,725,437.
- Formulations of TCDO are of particular interest in the present invention.
- WF10 is a
- TCDO TCDO formulation of particular interest in the practice of the invention.
- WFIO also known as Oxoferin (Oxo Chemie GmbH, Fort Worth, Tex.)
- Oxoferin Oxo Chemie GmbH, Fort Worth, Tex.
- Other formulations of TCDO are within the scope of this invention.
- Chlorite-containing compositions can be formulated for parenteral or enteral administration, generally parenteral administration. Accordingly, formulations of chlorite are suitable for parenteral, topical, or transdermal administration, usually intravenous, intramuscular, or subcutaneous administration, and may be suitable for administration by bolus injection, sustained release (including controlled release), infusion, and the like. Administration by infusion (e.g., by subcutaneous or intravenous infusion) is of interest, as is administration in the form of suppositories. Additional agents and therapies
- Chlorite can be administered alone or in various combinations. Where administered in combination, chlorite can be administered in conjunction with other agents, particularly those suitable for protective, palliative or supportive care of the subject.
- the phrase "in conjunction with” means that an agent is administered prior to, concurrently, or after other substance or therapy. Examples of agents for administration in conjunction with an agent include, but are not limited to, riluzole. Other agents for administration in conjunction with chlorite include agents for control of symptoms of a macrophage-associated neurodegenerative disorder, such as ALS, AD or MS symptoms.
- agents for administration in conjunction with chlorite according to the invention include, but are not limited to, baclofen, diazepam, trihexyphenidyl and/or amitriptyline.
- Chlorite can also be administered in conjunction with non-drug therapy (e.g., physical and/or occupational therapy, massage, and the like).
- the composition does not contain an amount of another anti- proliferative agent, such as a polyamine analog, effective to decrease the level of abnormal macrophages in a macrophage-associated neurodegenerative disorder patient, such as an ALS, AD, or MS patient (e.g., as compared to prior to therapy).
- a macrophage-associated neurodegenerative disorder patient such as an ALS, AD, or MS patient (e.g., as compared to prior to therapy).
- TCDO has been described for administration in combination therapy with anti-proliferative agents where TCDO is administered in an amount effective to promote macrophage phagocytosis to facilitate delivery of the anti-proliferative agent to the macrophage.
- chlorite ions e.g., as a pharmaceutically acceptable salt or in a stabilized matrix, such as in TCDO
- a macrophage-associated neurodegenerative disorder patient such as an ALS, AD or MS patient
- the chlorite is the active ingredient present in the subject in an amount effective to facilitate treatment of the patient e.g., through reduction in proliferating/inappropriately activated macrophages, and without the need for administration of ,for example, a polyamine analog or other anti-proliferative agent in conjunction with chlorite.
- Administration and dosing are administered to a macrophage-associated neurodegenerative disorder patient, such as an ALS, AD or MS patient so that the chlorite is the active ingredient present in the subject in an amount effective to facilitate treatment of the patient e.g., through reduction in proliferating/inappropriately activated macrophages, and without the need for administration of ,for example, a polyamine analog or other anti-proliferative agent in conjunction with chlorite.
- Chlorite formulations are generally dosed in vivo corresponding to the body weight of the subject. Due to the continuous breakdown of the active agent in the blood, the agent is normally administered at regular intervals. Those of skill in the art will readily appreciate that actual dosages and regimen will vary as a function of the agent, formulation, the severity of the symptoms, the susceptibility of the subject to treatment and/or side effects, and the like. Dosages are readily and routinely determinable by those of skill in the art by a variety of means.
- Exemplary doses of chlorite-containing formulations can vary between about 0.1 ml/kg to about 1.5 ml/kg, preferably, about 0.5 ml/kg of body weight and at a concentration of about 40 to about 80 mMol ClO 2 " per liter, usually about 60 mMol ClO 2 " per liter, respectively.
- TCDO a dose finding phase I/II study evaluating WF-10 administered intravenously and involving 48 patients established a maximum dose of approximately 0.5 ml/kg.
- Other suitable doses may be approximately 0.25 ml/kg.
- the regimen of administration (e.g., dose combined with frequency of administration) will generally involve administration in an amount and at a frequency to provide for a desired effect, e.g., administration of an amount effective to provide for improvement in one or more symptoms of a macrophage-associated neurodegenerative disorder patient, such as one or more ALS, AD or MS symptoms.
- a macrophage-associated neurodegenerative disorder patient such as one or more ALS, AD or MS symptoms.
- chlorite can be administered for 2, 3, 4, 5, 6, 7, 8, 9, 10 or more consecutive days, which administration period may be reinitiated after 1, 2, 3 or more weeks following the last dose.
- a WF-10 regimen comprises 5 consecutive days of treatment every 3 weeks.
- chlorite is administered so as to effect modulation of macrophage proliferation, e.g., alteration of the level of proliferating macrophages or the rate of macrophage proliferation compared to in the absence of agent administration, and/or to effect modulation of inappropriate macrophage activation.
- An effective amount of chlorite is determined by, for example, comparing the level (or number) of promacs , before and during treatment, with a downward trend in the number of promacs generally being consistent with a positive effect.
- chlorite is administered so as to effect a change in the level of proliferating macrophages or the rate of macrophage proliferation of at least 25%, preferably at least 50%, more preferably at least 75%, and even more preferably at least 90%.
- the degree of modulation may be assessed by measurement of macrophage proliferation as described in the art, and generally entails detecting a proliferation marker(s) in a macrophage population or uptake of certain substances such as BrdU or 3H-thymidine (which would provide a quantitative measure of proliferation) (see, e.g., U.S. Publication No. 20030175832).
- proliferating macrophages may be detected by assaying cell proliferative markers, such as PCNA, Ki67 or uptake of bromodeoxyuridine (BrdU) or 3H-thymidine. These markers are distinct from those that identify only "activated" macrophages (as opposed to proliferating macrophages), such as CD69 and CD25.
- the cellular subset representing macrophages may in turn be identified by detection of certain cell specific markers, such as CD14, CD68, CD16, or nonspecific esterase. Detection of these cell-type and/or proliferative markers use methods standard in the art, such as staining techniques and FACS sorting and analysis.
- chlorite is administered to as to effect a decrease in the level
- pathologic macrophages e.g., to effect a decerase in the level of CD14+ monocytes, preferably activated CD 14+ monocytes, in a patient with a macrophage-associated neurodegenerative disorder (e.g., a patient with ALS, with AD, or with MS).
- a macrophage-associated neurodegenerative disorder e.g., a patient with ALS, with AD, or with MS.
- chlorite is administered in an amount sufficient to decrease the level of (e.g., number of) CD 14+ monocytes, preferably activated CD 14+ monocytes and/or CD 14+ monocytes with elevated HLA-DR expression and/or the number of CD14+/CD16+ cells and/or the percentage of CD 16+ cells in a population of CD 14+ cells in the individual (i.e., an effective amount).
- An effective amount of chlorite is determined by, for example, comparing the level of number of CD 14+ monocytes, preferably activated CD 14+ monocytes, before and during treatment, with a downward trend of number of CD 14+ monocytes generally being consistent with a positive effect.
- An "amount sufficient to decrease the number of CD 14+ monocytes” preferably is able to decrease the number of CD 14+ monocytes by at least about 25%, preferably at least about 50%, more preferably at least about 75%, and even more preferably at least about 90%.
- Methods for assessing levels of CD 14+ monocytes, activated CD 14+ monocytes, CD 14+ monocytes with elevated HLA-DR expression, CD14+/CD16+ cells and the percentage of CD 16+ cells in a population of CCD 14+ are known in the art (see, e.g., U.S. Publication No. 20030175832). Such a decrease may have desirable concomitant effects, such as to palliate, ameliorate, stabilize, reverse, slow and/or delay progression of disease, delay or even prevent onset of disease.
- macrophage proliferation rate CD 14+ cells, HLA-DR expression, and the like as set out above can be compared to a level from the same individual measured at a different time and/or under different conditions (such as before treatment, different dose, etc.), and/or to a mean or median level determined for a non-diseased standard (e.g., non- macrophage-associated neurodegenerative disorder patient, such as a non-ALS, non-AD, or non-MS, as appropriate), for example from an unaffected individual (e.g., non- macrophage-associated neurodegenerative disorder individual or individuals; a non-ALS individual or non-ALS individuals; or non-AD individual or non-AD individuals; or non-MS individual or non-MS individuals).
- a non-diseased standard e.g., non- macrophage-associated neurodegenerative disorder patient, such as a non-ALS, non-AD, or non-MS, as appropriate
- an unaffected individual e.g., non- macrophage-associated neurodegenerative
- an HLA-DR expression level may be compared to an HLA-DR level from the same individual measured at a different time and/or under different conditions (such as before treatment, different dose, etc.).
- an HLA-DR expression level is compared to a mean or median level of HLA-DR expression determined on a population of CD14+ cells from a non-diseased (e.g., non-ALS, non-AD, or non-MS) standard, for example from a non-ALS individual or non-ALS individuals, or non-MS individual or non-MS individuals, or non-AD individual or non-ADindividuals).
- a non-diseased e.g., non-ALS, non-AD, or non-MS
- a finding of HLA-DR expression level of greater than about 1.4 fold that of the non-diseased standard is indicative of an elevated level of HLA-DR expression in the individual.
- a finding of HLA-DR expression level of greater than about 1.5 fold, greater than about 1.6 fold, greater than about 1.7 fold, greater than about 1.8 fold, greater than about 1.9 fold, greater than about 2.0 fold, greater than about 5.0 fold, or greater than about 10 fold that of a non-diseased standard is indicative of an elevated level of HLA-DR expression in the individual.
- a macrophage-associated neurodegenerative disorder subject e.g., an ALS subject, an AD subject, or an MS subject
- a non-diseased subject e.g., non-ALS, non-AD, or non-MS subject
- the number of CD 14+/CD 16+ cells or the percentage of CD 16+ cells in a population of CD 14+ cells in a sample from a macrophage-associated neurodegenerative disorder subject is compared to a mean or median level of CD14+/CD16+ cells in a biological sample from a non- disease (e.g., non-ALS, non-AD, or non-MS) standard, for example from a non-ALS individual or non-ALS individuals; or non-AD individual or non-AD individuals or non-MS individual or non-MS individuals.
- a non- disease e.g., non-ALS, non-AD, or non-MS
- therapy according to the invention is provided so as to decrease the number of CD14+/CD16+ cells or the percentage of CD 16+ cells in a population of CD 14+ cells so as to more closely approximate such in an appropriate non-diseased subject.
- therapy is monitored by following blood macrophage activation, usually by following CD14/DR levels and the percentage of CD14/16 positive cells as described above.
- Kits with unit doses of the subject compounds are provided.
- kits in addition to the containers containing the unit doses will be an informational package insert describing the use and attendant benefits of chlorite in treating a macrophage-associated neurodegenerative disorder subject, such as ALS, AD, or MS.
- Preferred compounds and unit doses are those described herein above.
- individuals suitable for therapy involving administration of chlorite according to the invention include individuals who have been diagnosed as having a macrophage-associated neurodegenerative disorder, are "afflicted with" a macrophage- associated neurodegenerative disorder (e.g., diagnosed as having, suffering from and/or displaying one or more clinical symptoms), or who have been adjudged to be at high risk for developing such a disorder.
- An "at risk” or “high risk” individual is an individual who has a discrete and significant risk of developing a macrophage-associated neurodegenerative disorder.
- An “at risk” or “high risk” individual may or may not have detectable disease, and may or may not have displayed detectable disease prior to receiving the method(s) described herein.
- High risk denotes that an individual has one or more so-called risk factors, which are measurable parameters that correlate with development of disease. An individual having one or more of these risk factors has a higher probability of developing disease than an individual without these risk factor(s).
- risk factors include, but are not limited to, genetic (i.e., hereditary) considerations (including family history and genetic markers). It is understood that having only one risk factor can often indicate high risk.
- the clinician has discretion to determine whether treatment using an agent may be indicated for an individual at risk.
- Exemplary a macrophage-associated neurodegenerative disorders includes ALS, AD, and MS.
- individuals suitable for therapy involving administration of chlorite according to the invention include individuals who have been diagnosed as having
- ALS are "afflicted with” ALS (e.g., diagnosed as having, suffering from and/or displaying one or more clinical symptoms of) ALS, or who have been adjudged to be at high risk for developing such a disorder.
- An “at risk” or “high risk” individual is an individual who has a discrete and significant risk of developing ALS.
- An “at risk” or “high risk” individual may or may not have detectable disease, and may or may not have displayed detectable disease prior to receiving the method(s) described herein.
- “High risk” (or "at risk”) denotes that an individual has one or more so-called risk factors, which are measurable parameters that correlate with development of disease.
- risk factors include, but are not limited to, genetic (i.e., hereditary) considerations (including family history and genetic markers). It is understood that having only one risk factor can often indicate high risk.
- the clinician as one skilled in the art, has discretion to determine whether treatment using an agent may be indicated for an individual at risk.
- Exemplary clinical symptoms of ALS include muscle weakness, muscle wasting, muscle cramping, muscle twitching, slurred or slow speech, difficulty swallowing, and slow, uncoordinated movements.
- Further exemplary clinical symptoms of ALS include those detectable in a biological sample obtained from a subject having or suspected of having ALS, e.g., increased CD4:CD8 cell ratio compared to normal, decreased number of CD 14+ cells compared to normal, increased expression of HLA-DR on CD 14+ cells compared to normal CD 14+ cells, increased levels of activated monocytes or macrophages compared to normal, the presence of proliferating macrophages, and decreased serum IgG and/or IgM compared to normal, where "normal” as used herein means a subject unaffected by ALS or cells from such an unaffected subject.
- individuals suitable for therapy involving administration of chlorite according to the invention include individuals who have been diagnosed as having MS, are "afflicted with” MS (e.g., diagnosed as having, suffering from and/or displaying one or more clinical symptoms of) MS, or who have been adjudged to be at high risk for developing such a disorder.
- An "at risk” or “high risk” individual is an individual who has a discrete and significant risk of developing MS.
- An “at risk” or “high risk” individual may or may not have detectable disease, and may or may not have displayed detectable disease prior to receiving the method(s) described herein.
- High risk denotes that an individual has one or more so-called risk factors, which are measurable parameters that correlate with development of disease. An individual having one or more of these risk factors has a higher probability of developing disease than an individual without these risk factor(s).
- risk factors include, but are not limited to, genetic (i.e., hereditary) considerations (including family history and genetic markers). It is understood that having only one risk factor can often indicate high risk.
- the clinician as one skilled in the art, has discretion to determine whether treatment using an agent may be indicated for an individual at risk.
- Exemplary clinical symptoms of MS include those detectable in a biological sample obtained from a subject having or suspected of having MS, e.g., increased CD4:CD8 cell ratio compared to normal, decreased number of CD 14+ cells compared to normal, increased expression of HLA-DR on CD 14+ cells compared to normal CD 14+ cells, increased levels of activated monocytes or macrophages compared to normal, the presence of proliferating macrophages, and decreased serum IgG and/or IgM compared to normal, where "normal” as used herein means a subject unaffected by MS or cells from such an unaffected subject.
- individuals suitable for therapy involving administration of chlorite according to the invention include individuals who have been diagnosed as having AD, are "afflicted with” AD (e.g., diagnosed as having, suffering from and/or displaying one or more clinical symptoms of) AD, or who have been adjudged to be at high risk for developing such a disorder.
- An "at risk” or “high risk” individual is an individual who has a discrete and significant risk of developing AD.
- An “at risk” or “high risk” individual may or may not have detectable disease, and may or may not have displayed detectable disease prior to receiving the method(s) described herein.
- High risk denotes that an individual has one or more so-called risk factors, which are measurable parameters that correlate with development of disease. An individual having one or more of these risk factors has a higher probability of developing disease than an individual without these risk factor(s).
- risk factors include, but are not limited to, genetic (i.e., hereditary) considerations (including family history and genetic markers). It is understood that having only one risk factor can often indicate high risk.
- the clinician as one skilled in the art, has discretion to determine whether treatment using an agent may be indicated for an individual at risk.
- Exemplary clinical symptoms of AD include mild forgetfulness, including trouble remembering recent events, activities, or the names of familiar people or things; difficulty in solving simple math problems; trouble remembering how to do simple tasks (e.g., brushing teeth or combing hair); inability to think clearly; difficulty spekaing, understanding, reading, or writing; and anxiety or aggressivness, or tendency to wander away from home.
- Further exemplary clinical symptoms of AD include those detectable in a biological sample obtained from a subject having or suspected of having AD, e.g., increased CD4:CD8 cell ratio compared to normal, decreased number of CD 14+ cells compared to normal, increased expression of
- HLA-DR on CD 14+ cells compared to normal CD 14+ cells increased levels of activated monocytes or macrophages compared to normal, the presence of proliferating macrophages, and decreased serum IgG and/or IgM compared to normal, where "normal” as used herein means a subject unaffected by AD or cells from such an unaffected subject.
- Chlorite-based therapy according to the invention can be monitored, and dosages and regimen adjusted accordingly, by assessing the effect of therapy upon one or more clinical symptoms.
- an effective amount of chlorite is a dose or doses that provide for an improvement in one or more clinical symptoms in the subject.
- a macrophage-associated neurodegenerative disorder e.g., ALS, AD, MS
- monitoring these levels can be used to facilitates assessment of initial responsiveness to therapy and/or efficacy, as well as the appropriate dosage of the therapy.
- monitoring therapy means that symptoms are assessed at different times and are compared over time. Where assessment of a clinical symptom requires analysis of a biological sample, such biological sample(s) are generally obtained at different times, for example, during application of therapy, and are compared, either with each other, a control, and/or a desired value. Methods for monitoring ALS therapy through assessment of biological samples is described in, for example, U.S. Publication No. 20030175832.
- therapy for a macrophage-associated neurodegenerative disorder such as
- monitoring therapy includes the step of determining the level of CD 14+ cells expressing elevated HLA-DR in a blood sample, preferably peripheral blood.
- monitoring therapy includes the step of determining the percentage of CD 16+ cells in the population of CD 14+ cells in a blood sample, preferably peripheral blood.
- monitoring therapy includes the step of determining the number of CD14+/CD16+ cells in a blood sample, preferably peripheral blood.
- the level of abnormal macrophages in various embodiments, the level of CD 14+ cells expressing elevated HLA-DR; the percentage of CD 16+ cells in the population of CD 14+ cells and/or the number of CD14+/CD16+ cells
- monitoring therapy also includes the step of measuring proliferation of the abnormal macrophages.
- therapy for a macrophage-associated neurodegenerative disorder is monitored by assessing the level of abnormal macrophages in a sample taken at a particular time from a patient undergoing the therapy and/or a sample taken after or at completion of the therapy is generally compared with the level in a sample taken from the patient prior to the therapy and/or with the level in a sample taken from the patient at a different time point in the therapy. For example, a decrease in the level of abnormal macrophages in the sample taken during therapy as compared to the sample taken prior to or at an earlier time point in therapy would generally be consistent with a positive effect of the therapy.
- therapy according to the invention is monitored by assessing the level of abnormal macrophages is assessed by the determining the level of HLA-DR expression by CD 14+ cells from a blood sample, such as a peripheral blood sample.
- a blood sample such as a peripheral blood sample.
- the effect of a therapy is determined by comparing the level of HLA-DR expression by CD 14+ cells in peripheral blood before and during treatment, with a downward trend in HLA-DR expression generally being consistent with a positive effect.
- therapy according to the invention is monitored by assessing the level of pathologic macrophages, e.g., by assessing the level of abnormal macrophages is assessed by the determining the percentage of CD 16+ cells in the population of CD 14+ cells from a blood sample, such as a peripheral blood sample.
- a blood sample such as a peripheral blood sample.
- the effect of a therapy is determined by comparing the percentage of CD 16+ cells in the population of CD 14+ cells in peripheral blood before and during treatment, with a downward trend in the percentage of CD14+/CD16+ cells generally being consistent with a positive effect.
- therapy according to the invention is monitored by assessing the level of pathologic macrophages, e.g., by assessing the level of abnormal macrophages is assessed by the determining the number of CD14+/CD16+ cells in a blood sample, such as a peripheral blood sample.
- a blood sample such as a peripheral blood sample.
- the effect of a therapy is determined by comparing the number of CD14+/CD16+ cells in peripheral blood before and during treatment, with a downward trend in the number of CD14+/CD16+ cells generally being consistent with a positive effect.
- the invention also contemplates kits with unit doses of a source of chlorite ions, e.g., a chlorite salt (e.g., alkali metal salt, e.g., sodium chlorite, potassium chlorite, and the like); a mixture of chlorite salts; a matrix of chlorite ions, e.g., a compositions having the general formula ClO 2 x nO 2 , wherein "n" can be a value of about 0.1-0.25; e.g.,. TCDO.
- a source of chlorite ions e.g., a chlorite salt (e.g., alkali metal salt, e.g., sodium chlorite, potassium chlorite, and the like); a mixture of chlorite salts; a matrix of chlorite ions, e.g., a compositions having the general formula ClO 2 x nO 2 , wherein "n" can be a value of about 0.1-0.
- kits in addition to the containers containing the unit doses will be an informational package insert describing the use and attendant benefits of chlorite in treating a macrophage-associated neurodegenerative disorder subject, such as ALS, AD, or MS.
- the kit includes information relating to identification of patients having a macrophage-associated neurodegenerative disease and monitoring of therapy of such patients (e.g., information relating to assessment of pathologic macrophages, e.g.,. proliferating macrophages, activated macrophages).
- ALSFRS-R Revised ALS Functional Rating Scale
- ALSFRS-R Revised ALS Functional Rating Scale
- the forty patients consisted of 26 men (age range, 34-87 yr; mean age ⁇ SD, 58.0 ⁇
- the monocyte granularity associated with its differentiation was measured by CD14-associated "backgating" on side light-scatter characteristics (SSC).
- SSC side light-scatter characteristics
- FITC CD14-fluorescein isothiocyanate
- PE CD16-phycoerythrin
- PerCP CD4- peridinin chlorophyll protein
- Negative controls consisted of aliquots stained with isotype IgG- FITC, IgG-PE, and IgG-PerCP; all staining was performed as per manufacturers specifications.
- Plasma from ALS patient blood was obtained by Percoll gradient centrifugation, and was frozen at -70°C until use.
- Standard ELIS A for determination of serum antibody Anti- Human IgG Fab or anti-Human IgM (Sigma, St. Louis, Missouri, USA) were coated (100 mcl/well) into 96-well ELIS A plates (Nunc, Roskilde, Denmark) by incubation for at least one hour at 37°C.
- the plates were washed one time with TBS (150 mM NaCl, 20 mM Tris-HCl, pH7.4), then blocked for 30 minutes by addition of 150 mcl (microliters)/well of BLOTTO (TBS plus 0.1%) Tween-20, 2.5% normal goat serum, 2.5%) non fat dry milk) at room temperature, with gentle rocking.
- ELISA plates were subsequently washed once (IX) with TBS. Serial dilutions of serum were added to coated plates (duplicate wells each dilution, 100 mcl/well) and allowed to react for 90 minutes, room temperature.
- Bound IgM antibodies were detected by adding 100 mcl/well of anti-Human IgM alkaline phosphatase- conjugate (Kirkegaard & Perry, Gaithersburg, Maryland, USA) diluted 1:5000 in BLOTTO. Antibody conjugates were incubated for 8one hour at room temperature with gentle agitation. Conjugates were removed by aspiration and plates washed 4X with TBS. Development of color reaction was effected by addition of 100 mcl of PNPP substrate (Sigma) to each well, followed by incubation for 20 minutes at room temperature. The optical density (O.D.) in each well was read at 405nm. Any sera with exceptionally low or high values were re-tested.
- EXAMPLE 1 CROSS-SECTION STUDY OF IMMUNE ACTIVATION IN ALS PATIENTS COMPARED TO NORMAL SUBJECTS
- CD14+ monocytes from patients with ALS expressed significantly higher than normal levels of major histocompatibility (MHC) antigen class II (HLA-DR) (P ⁇ 0.0001) (Table 2).
- MHC major histocompatibility
- Perivascular macrophages normally constitutively express MHC Class II (HLA-DR), which is upregulated in response to injury (Streit et al. 1989. Expression of la antigen on perivascular and microglial cells after sublethal and lethal motor neuron injury. Exp. Neurol. 105:115-126).
- CD4/CD38 reactivity was significantly lower in patients with ALSFRS-R score of 24 or lower (P ⁇ 0.01) whereas no difference of CD4/CD38 reactivity was found in ALS patients with less severe disease (ALSFRS-R score >24). No significant disease associated changes were observed in any of the other T cell (CD4 or CD8) parameters measured.
- EXAMPLE 3 MACROPHAGE ACTIVATION AND ALS DISEASE PROGRESSION
- EXAMPLE 4 CHANGES OF SERUM-IGG AND -IGM IN PATIENTS WITH ALS
- Table 2 shows that the concentration of IgG and IgM in serum was significantly different in patients with ALS as compared to normal controls. Levels of serum-IgG and -IgM also varied with disease severity. ALS patients with ALSFRS-R scores of 0-24 had significantly lower levels of serum-IgG than normal controls (P ⁇ 0.05) and serum-IgG levels were similar in both individuals with milder disease and controls (Figure 3 a). However, serum- IgM levels were significantly higher in individuals with milder disease (P ⁇ 0.01) and not significantly different between normal controls and in individuals with severe disease (Figure 3b).
- EXAMPLE 5 THERAPY RELATED CHANGES IN ALS SPECIFIC IMMUNE ACTIVATION STATUS
- Table 1 shows the medications that patients with ALS were taking at the time of assessment in the current study. The drugs fell into two different categories; riluzole approved for slowing ALS disease progression and nonsteroidal anti-inflammatory drugs (NSAIDS).
- Table 3 summarizes the effects of medication treatments on immune activation measurements in patients with ALS. In particular, levels of macrophage activation and differentiation as measured by HLA-DR and CD 16 did not change with therapy.
- n 80 for control samples for serum-IgG and -IgM.
- HLA-DR The significantly higher levels of HLA-DR on the circulating monocytes in patients with ALS may be attributed to the reaction of peripheral immune system to motor neuron injury, extending the reaction of microglia/macrophages in the spinal cord and brain in patients with ALS.
- activated macrophages in the blood of patients with ALS may communicate with spinal cord perivascular areas and play a direct pathogenic role in disease
- CD14+/CD16+ monocytes are a subpopulation of cells that while in the circulation acquire features in common with mature tissue macrophages. They are able to produce pro- inflammatory cytokines, such as TNFalpha, IL-1 alpha, and IL-6, but their expression of the potent antiinflammatory cytokine IL-10 is low or absent. Therefore, CD14+/CD16+ cells may induce more pronounced levels of inflammation than regular monocytes.
- CD 14+/CD 16+ monocytes can rapidly migrate to the site of inflammation, where they readily mature into proinflammatory macrophages.
- neurological disorders such as Alzheimer's disease (AD) and AIDS-related dementia may be due in part to neurotoxic factors released by these cells when migrating into the CNS and crossing the BBB.
- Elevated levels of HLA-DR expression on CD 16 expressing monocytes might result in blood monocytes migrating into the CNS and crossing the BBB in ALS, by mechanisms similar to the activated macrophages in AD and HAD.
- the decrease of the absolute percent of CD 14 cells in patients with ALS may be associated with the migration of circulating CD14/CD16+ cells to perivascular regions of disease, where these cells release local neurotoxic factors such as IL-6, a factor implicated as potentially playing pathogenic roles in ALS (Ono et al. 2001. Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis. J Neurol. Sci. 187:27-34; Sekizawa et al. 1998. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J. Neurol. Sci. 154:194-199), that could damage the motor neurons, similar to AIDS-related dementia and other HIV-associated neurological disorders.
- IL-6 local neurotoxic factors
- This Th2-like lymphocytic immune response could be induced by the presence of high levels of activated CD14+/CD16+ monocytes in ALS.
- Fc ⁇ R (CD 16) ligation on activated macrophages may change the phenotype of these activated macrophages to cells that preferentially drive a Th2-like response and result in the alteration of the Thl type adaptive component of the immune system.
- ALS Persistent disease-associated macrophage activation was observed in ALS blood and levels of HLA-DR on CD 14 cells was directly associated with rate of ALS disease progression.
- Th current study confirms systemic macrophage activation in ALS disease, implicating an active role of macrophages in ALS pathogenesis. Abnormally activated macrophages without evidence of concomitant T-cell activation was observed in ALS blood.
- IMMUNOKINETM The drug in each case was used at the same dose with the same interval between doses for each patient.
- Patient 1 received 5 cycles; patient 2 received 4 cycles. No adverse side effects were noted in either patient.
- Patient 1 is 59 y.o.
- ALS/FRS a known mutation in the superoxide dismutase gene, SOD
- SOD superoxide dismutase gene
- the rate of ALS progression based on the ALS/FRS scoring system is essentially linear, with ALS progressing at a predictable rate after the slope of decline is known.
- the predicted rate of disease progression is shown as a projected dotted line extending from the solid declination lines in the ALS/FRS scores.
- the Patient 1 could no longer swallow food or fluids and had had a gastrointestinal tube(G-tube) placed into her stomach for feeding purposes.
- the inability to eat is a sign of brain involvement with the degenerative ALS process, whereas the ALS/FRS measurement documents the spinal cord degeneration.
- Patient 2 This 37 y.o.man, diagnosed with a sporadic (non familial)form of ALS in
- Fig. 4 is shows changes in blood macrophage activation results in Patient 1 as a result of treatment with WF10.
- the Y axis represents Units of HLA-DR expressed on the surface of blood CD 14 cells (monocyte/macrophages).
- the second column shows the level of DR expression exhibited by ALS patients with a rapidly declining clinical course.
- the third column shows the level of DR expression in an ALS patient with slowly progressive disease. The progression rates between these two columns differs by approximately 5-10 fold (Figs 2a and 2b).
- the patients with high levels of DR progress 5-1 Ox faster than those with low levels of DR.
- the first set of columns in Fig. 4 shows the baseline level of DR (high, fast progressor) in the ALS patient, with the second column representing the level of DR expressed tliree weeks after one 5 day cycle of WF10 (0.5cc/kg of WF10, a 63mM solution of chlorite containing solution, infused over 1 hour in 500cc of saline each day for three days).
- the third column in the first set of columns represents the normal (38 normal blood donor composite) level of DR expression on CD 14 cells +/- 1 standard deviation.
- Fig. 5 is a composite set of curves representing blood macrophage activation measurements taken from a patient with multiple sclerosis (MS) who received WFIO therapy as described in Example 6 above with one cycle of WF10.
- the values along the Y axis represent the ratio of the observed measurement for each of the parameter measured divided by the normal level (38 normal donor mean value) to yield a ratio.
- Day 0 represents baseline values for 5 different macrophage activation/proliferation markers. Each of the 5 markers were elevated beyond normal range (shown by the solid and dotted lines) at Day 0.
- EXAMPLE 8 ANALYSIS OF MACROPHAGES OF ALS AND AD PATIENTS [00141] A cross-sectional study of immune activation was performed on blood from 38 patients diagnosed with sALS as compared to control groups with initial statistical analyses performed independent of drug treatment status. In the present investigation two control groups were chosen to compare with sALS patients: 28 age-matched normal controls and 25 AD patients as neurological disease controls. Blood cells from patients with sALS, similar to disease control AD patients, showed abnormal levels of activation. Table 4 summarizes the results of this study. Patients with sALS and AD had significantly higher proportional levels of the CD4 T lymphocyte subset as compared to normal controls (p ⁇ 0.05).
- the aberrant monocytic phenotype defined by higher expression of HLA-DR and CD 16 was associated with significant differences inCD14-associated SSC (measure of granularity and differentiation) between patients with sALS and normal controls. Compared with normal controls, monocytes from sALS patients had statistically increased granularity (higher SSC values) ( pb ⁇ .01). Finally, the overall status of humoral immunity was evaluated by quantitating levels of serum-IgG and - IgM in patients with sALS and normal controls (Table 4); serum-IgG levels in patients with sALS were significantly lower than normal controls ( p ⁇ 0.003), whereas, serum-IgM concentrations were significantly higher ( p ⁇ 0.03) (sera from the AD patients were not available for study).
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005213300A AU2005213300B2 (en) | 2004-02-03 | 2005-01-25 | Chlorite in the treatment of neurodegenerative disease |
EP05722556.7A EP1711191B1 (en) | 2004-02-03 | 2005-01-25 | Chlorite in the treatment of amyotrophic lateral sclerosis |
CN2005800037236A CN101102781B (en) | 2004-02-03 | 2005-01-25 | Chlorite in the treatment of neurodegenerative disease |
JP2006552151A JP5072367B2 (en) | 2004-02-03 | 2005-01-25 | Chlorous acid in the treatment of neurodegenerative diseases |
CA2554511A CA2554511C (en) | 2004-02-03 | 2005-01-25 | Chlorite in the treatment of neurodegenerative disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54157604P | 2004-02-03 | 2004-02-03 | |
US60/541,576 | 2004-02-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005076819A2 true WO2005076819A2 (en) | 2005-08-25 |
WO2005076819A3 WO2005076819A3 (en) | 2006-04-13 |
Family
ID=34860199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/002469 WO2005076819A2 (en) | 2004-02-03 | 2005-01-25 | Chlorite in the treatment of neurodegenerative disease |
Country Status (7)
Country | Link |
---|---|
US (5) | US7105183B2 (en) |
EP (2) | EP1711191B1 (en) |
JP (3) | JP5072367B2 (en) |
CN (2) | CN102423318B (en) |
AU (1) | AU2005213300B2 (en) |
CA (2) | CA2554511C (en) |
WO (1) | WO2005076819A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2910811A1 (en) * | 2007-01-03 | 2008-07-04 | Ass Pour Le Dev De La Biothera | Use of riluzole for preparation of drug e.g. to reestablish immune function, to treat inflammatory diseases, infection, cancer, viral infection and their virological and immunitary symptoms, leishmaniasis, malaria or bilharziasis |
US8067035B2 (en) | 2005-12-22 | 2011-11-29 | Neuraltus Pharmaceuticals, Inc. | Chlorite formulations, and methods of preparation and use thereof |
WO2015175974A1 (en) * | 2014-05-16 | 2015-11-19 | Neuraltus Pharmaceuticals, Inc. | Methods and compositions for treatment of macrophage-related disorders |
US10822421B2 (en) | 2012-08-31 | 2020-11-03 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005510524A (en) * | 2001-11-16 | 2005-04-21 | アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド | Treatment of neurodegenerative disorders by modulating the polyamine pathway |
US7105183B2 (en) | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
ATE473443T1 (en) * | 2004-07-16 | 2010-07-15 | Gyros Patent Ab | GRADING OF IMMUNE RESPONSES |
US20060264783A1 (en) | 2005-05-09 | 2006-11-23 | Holmes Elizabeth A | Systems and methods for monitoring pharmacological parameters |
CN101253409A (en) * | 2005-08-02 | 2008-08-27 | 埃克斯生物科技公司 | Diagnosis, treatment, and prevention of vascular disorders using IL-1alpha autoantibodies |
AU2013234421B2 (en) * | 2005-12-22 | 2015-08-27 | Neuraltus Pharmaceuticals, Inc. | Chlorite formulations, and methods of preparation and use thereof |
US11287421B2 (en) | 2006-03-24 | 2022-03-29 | Labrador Diagnostics Llc | Systems and methods of sample processing and fluid control in a fluidic system |
US8741230B2 (en) | 2006-03-24 | 2014-06-03 | Theranos, Inc. | Systems and methods of sample processing and fluid control in a fluidic system |
US8007999B2 (en) | 2006-05-10 | 2011-08-30 | Theranos, Inc. | Real-time detection of influenza virus |
US20110008282A1 (en) * | 2006-05-15 | 2011-01-13 | Xbiotech, Inc. | IL-1alpha immunization induces autoantibodies protective against atherosclerosis |
CN102580086A (en) * | 2006-05-22 | 2012-07-18 | 埃克斯生物科技公司 | Treatment of cancer with anti-IL-1[alpha] antibodies |
US20080113391A1 (en) | 2006-11-14 | 2008-05-15 | Ian Gibbons | Detection and quantification of analytes in bodily fluids |
US8158430B1 (en) | 2007-08-06 | 2012-04-17 | Theranos, Inc. | Systems and methods of fluidic sample processing |
PL2285409T3 (en) * | 2008-05-30 | 2016-10-31 | Il-1 alpha antibodies | |
CA2737056C (en) * | 2008-09-12 | 2018-10-30 | Xbiotech Inc. | Targeting pathogenic monocytes |
BR112012002333A2 (en) * | 2009-08-06 | 2017-07-18 | Neuraltus Pharmaceuticals Inc | method of reducing side effects and method of enhancing the effect of an immunomodulator administered to a subject in need thereof; methods for treating disease associated with overactivation of monocytes to activated macrophages, type II diabetes or related complications, disease associated with migration of activated monocytes or macrophages, disease associated with overproduction of scd14 and / or scd163 by activated macrophages; sodium chloride compound; pharmaceutical composition; method for diagnosing a macrophage-related disease in a subject; and method for determining the effectiveness of treatment with an oxidizing agent for macrophage related disease in a subject. |
BR112012009196B1 (en) | 2009-10-19 | 2021-03-30 | Labrador Diagnostics Llc | SYSTEM FOR MODELING THE PROGRESSION OF A DISEASE WITHIN A POPULATION |
WO2011111043A1 (en) * | 2010-03-10 | 2011-09-15 | Yeda Research And Development Co. Ltd | Cellular blood markers for early diagnosis of als and for als progression |
PT2582391T (en) | 2010-06-18 | 2019-01-11 | Xbiotech Inc | Arthritis treatment |
PT2605771T (en) * | 2010-08-16 | 2018-07-09 | Allergan Inc | Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists |
ES2622482T3 (en) | 2010-08-23 | 2017-07-06 | Xbiotech, Inc | Neoplastic disease treatment |
US9724409B2 (en) | 2011-04-01 | 2017-08-08 | Xbiotech, Inc. | Treatment of inflammatory skin disease |
CN108404127A (en) | 2011-09-23 | 2018-08-17 | 埃克斯生物科技公司 | Cachexia is treated |
CA2857604A1 (en) | 2011-12-22 | 2013-06-27 | Nuvo Research Gmbh | Liposomal chlorite or chlorate compositions |
US9545441B2 (en) | 2012-09-18 | 2017-01-17 | Xbiotech, Inc. | Treatment of diabetes |
EP3072513A1 (en) * | 2015-03-26 | 2016-09-28 | Medday | Biotin for treating Amyotrophic lateral sclerosis |
WO2017079161A2 (en) | 2015-11-02 | 2017-05-11 | Neuraltus Pharmaceuticals, Inc. | Treatment of neurodegenerative disease with sodium chlorite |
CN110382001A (en) | 2017-02-16 | 2019-10-25 | 埃克斯生物科技公司 | The treatment of suppurative hidradenitis |
JP7119017B2 (en) | 2020-03-13 | 2022-08-16 | 本田技研工業株式会社 | Straddle-type electric vehicle |
WO2023225125A1 (en) * | 2022-05-19 | 2023-11-23 | Neuvivo, Inc. | Biomarkers for neurogenerative disease |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4725437A (en) | 1985-05-02 | 1988-02-16 | Oxo Chemie Gmbh | Aqueous chlorite matrix solution |
US5877222A (en) | 1996-07-19 | 1999-03-02 | The Regents Of The University Of California | Method for treating aids-associated dementia |
WO1999017787A2 (en) | 1997-10-06 | 1999-04-15 | Oxo Chemie Ag | Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response |
US6086922A (en) | 1992-03-19 | 2000-07-11 | Oxo Chemie Ag | Use of a chemically-stabilized chlorite matrix for the parenteral treatment of HIV infections |
WO2001040517A2 (en) | 1999-11-30 | 2001-06-07 | Oxo Chemie Ag | Evaluating and predicting clinical outcomes by gene expression analysis |
WO2003048773A2 (en) | 2001-11-16 | 2003-06-12 | Slil Biomedical Corporation | Methods for monitoring amyotrophic lateral sclerosis |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3213389A1 (en) * | 1982-04-10 | 1983-10-20 | Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne | STABILIZED ACTIVATED OXYGEN AND MEDICINAL PRODUCTS CONTAINING THIS STABILIZED ACTIVATED OXYGEN |
US4576945A (en) * | 1982-10-26 | 1986-03-18 | Sanders Mark E | Hexaalkylmelamine-amino-oxy compounds |
US5051414A (en) * | 1989-08-03 | 1991-09-24 | Dupont Merck Pharmaceutical Company | Inhibition of HIV and other retroviruses by polyoxoanions |
US6099855A (en) * | 1992-06-25 | 2000-08-08 | Bioxy, Inc. | Therapeutic, production and immunostimulatory uses of biocidal compositions |
US5855922A (en) * | 1995-12-07 | 1999-01-05 | Bio-Cide International, Inc. | Antiseptic composition and process for prophylaxis and therapeutic treatment of dermal disorders |
US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
JP2001078775A (en) * | 1999-09-14 | 2001-03-27 | Kokuritsu Seishin Shinkei Center | Agent for controlling function of macrophage |
US6685754B2 (en) | 2001-03-06 | 2004-02-03 | Alchemix Corporation | Method for the production of hydrogen-containing gaseous mixtures |
US7105183B2 (en) * | 2004-02-03 | 2006-09-12 | The Regents Of The University Of California | Chlorite in the treatment of neurodegenerative disease |
-
2005
- 2005-01-24 US US11/042,816 patent/US7105183B2/en active Active
- 2005-01-25 EP EP05722556.7A patent/EP1711191B1/en active Active
- 2005-01-25 CN CN201110317862.3A patent/CN102423318B/en active Active
- 2005-01-25 CA CA2554511A patent/CA2554511C/en active Active
- 2005-01-25 WO PCT/US2005/002469 patent/WO2005076819A2/en active Application Filing
- 2005-01-25 AU AU2005213300A patent/AU2005213300B2/en active Active
- 2005-01-25 EP EP12192303.1A patent/EP2574342B1/en active Active
- 2005-01-25 CN CN2005800037236A patent/CN101102781B/en active Active
- 2005-01-25 JP JP2006552151A patent/JP5072367B2/en active Active
- 2005-01-25 CA CA2838392A patent/CA2838392C/en active Active
-
2006
- 2006-03-17 US US11/378,987 patent/US8029826B2/en active Active
-
2010
- 2010-10-07 US US12/900,361 patent/US20110053186A1/en not_active Abandoned
-
2011
- 2011-10-25 JP JP2011233850A patent/JP5797083B2/en active Active
-
2012
- 2012-04-27 US US13/458,954 patent/US9364501B2/en active Active
-
2015
- 2015-06-12 JP JP2015118841A patent/JP2015205901A/en active Pending
-
2016
- 2016-09-12 US US15/262,981 patent/US20170065634A1/en not_active Abandoned
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4725437A (en) | 1985-05-02 | 1988-02-16 | Oxo Chemie Gmbh | Aqueous chlorite matrix solution |
US6086922A (en) | 1992-03-19 | 2000-07-11 | Oxo Chemie Ag | Use of a chemically-stabilized chlorite matrix for the parenteral treatment of HIV infections |
US5877222A (en) | 1996-07-19 | 1999-03-02 | The Regents Of The University Of California | Method for treating aids-associated dementia |
WO1999017787A2 (en) | 1997-10-06 | 1999-04-15 | Oxo Chemie Ag | Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response |
WO2001040517A2 (en) | 1999-11-30 | 2001-06-07 | Oxo Chemie Ag | Evaluating and predicting clinical outcomes by gene expression analysis |
WO2003048773A2 (en) | 2001-11-16 | 2003-06-12 | Slil Biomedical Corporation | Methods for monitoring amyotrophic lateral sclerosis |
US20030130357A1 (en) | 2001-11-16 | 2003-07-10 | Tennore Ramesh | Use of polyamine analogs for amyotrophic lateral sclerosis |
US20030130350A1 (en) | 2001-11-16 | 2003-07-10 | Tennore Ramesh | Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis |
US20030158262A1 (en) | 2001-11-16 | 2003-08-21 | Tennore Ramesh | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
US20030175832A1 (en) | 2001-11-16 | 2003-09-18 | Marton Laurence J. | Methods for monitoring and treating amyotrophic lateral sclerosis |
Non-Patent Citations (51)
Title |
---|
ADAMSON ET AL., MOL. MED., vol. 5, 1999, pages 98 - 109 |
AKIYAMA ET AL., NEUROBIOL. AGING., vol. 21, 2000, pages 383 - 421 |
ANDERSON ET AL., J. LEUKOC. BIOL., vol. 72, 2002, pages 101 - 106 |
APPEL ET AL., J. NEUROL. SCI., vol. 118, 1993, pages 169 - 174 |
CEDARBAUM ET AL.: "The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function", J. NEUROL. SCI., vol. 169, 1999, pages 13 - 21 |
CREMER ET AL., N. ENGL. J. MED., vol. 295, 1976, pages 107 - 108 |
ENGELTHARDT ET AL., ARCH. NEUROL., vol. 47, 1990, pages 1210 - 1216 |
FISCHER-SMITH ET AL., J. NEUROVIROL., vol. 7, 2001, pages 528 - 541 |
FRANKENBERGER ET AL., BLOOD, vol. 87, 1996, pages 373 - 377 |
GASCON ET AL.: "Increased HLA-DR expression on peripheral blood monocytes in subsets of subjects with primary HIV infection is associated with elevated CD4 T-cell apoptosis and CD4 T-cell depletion", J. ACQUIR. IMMUNE. DEFIC. SYNDR., vol. 30, 2002, pages 146 - 153 |
GIESE ET AL., CELL IMMUNOL., vol. 229, no. 2, June 2004 (2004-06-01), pages 149 - 58 |
GIESE ET AL., TRANSPLANT. PROC., vol. 229, no. 2, June 2004 (2004-06-01), pages 149 - 58 |
GLASS ET AL., ANN. NEUROL., vol. 38, 1995, pages 755 - 762 |
GU ET AL.: "Time course of proinflammatory and anti-inflammatory responses after cardiac operation: monocyte HLA-DR expression", ANN. THORAC. SURG., vol. 76, 2003, pages 654 - 655 |
HANSEN ET AL., PHARMACOL TOXICOL., vol. 89, no. 2, August 2001 (2001-08-01), pages 92 - 5 |
HAYASHI ET AL., J. NEUROL. SCI., vol. 188, 2001, pages 3 - 7,9-12 |
HENSLEY ET AL., J. NEUROCHEM., vol. 82, 2002, pages 365 - 374 |
HIRSCH ET AL., ANN. NY. ACAD. SCI., vol. 991, 2003, pages 214 - 228 |
J. NEUROL. SCI., vol. 124, pages 96 - 107 |
KEMP ET AL., PHARMACOL TOXICOL., vol. 90, no. 6, June 2002 (2002-06-01), pages 346 - 8 |
KEMP ET AL., TRANSPLANT PROC., vol. 32, no. 5, August 2000 (2000-08-01), pages 1018 - 9 |
KLAUSTERMEYER ET AL., ANN. ALLERGY., vol. 63, 1989, pages 327 - 330 |
KOTT ET AL., NEUROLOGY, vol. 29, 1979, pages 1040 - 1044 |
LEHRICH ET AL., J. NEUROL. SCI., vol. 23, 1974, pages 537 - 540 |
LIU ET AL., J. NEUROVIROL., vol. 6, no. 11, 2000, pages 70 - 81 |
MARSHALL ET AL., BRAIN BEHAV. IMMUN., vol. 12, 1998, pages 297 - 307 |
MCGEER ET AL., EXP. GERONTOL., vol. 33, 1998, pages 371 - 378 |
MCGRATH E, PATHOBIOLOGY, vol. 67, 1999, pages 277 - 81 |
MCGRATH ET AL., CURR. OPIN. INVESTIG. DRUGS, vol. 3, 2002, pages 365 - 373 |
MCGRATH ET AL., TRANSPLANT. PROC., vol. 30, 1998, pages 4200 - 4204 |
MELICHAR ET AL.: "Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma", INT. J. GYNECOL. CANCER., vol. 13, 2003, pages 435 - 443 |
MORGAN ET AL., ARCH. DIS. CHILD., vol. 63, 1988, pages 771 - 773 |
NGUYEN ET AL., ANN. NEUROL., vol. 50, 2001, pages 630 - 639 |
NOTTET ET AL., J. IMMUNOL., vol. 156, 1996, pages 1284 - 1295 |
ONO ET AL.: "Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis", J. NEUROL. SCI., vol. 187, 2001, pages 27 - 34 |
OSTERMEYER-SHOAIB ET AL., ACTA NEUROL SCAND., vol. 87, 1993, pages 192 - 194 |
PROVINCIALI ET AL., ACTA. NEUROL. SCAND., vol. 78, 1988, pages 449 - 454 |
RAFFANTI ET AL., INFECTION., vol. 26, no. 4, July 1998 (1998-07-01), pages 202 - 7 |
SCHEMPP ET AL., ARZNEIMITTELFORSCHUNG, vol. 51, no. 7, 2001, pages 554 - 62 |
SCHIFFER ET AL., J. NEUROL. SCI., vol. 139, 1996, pages 27 - 33 |
See also references of EP1711191A4 |
SEKIZAWA ET AL.: "Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases", J. NEUROL. SCI., vol. 154, 1998, pages 194 - 199 |
STREIT ET AL.: "Expression of Ia antigen on perivascular and microglial cells after sublethal and lethal motor neuron injury", EXP. NEUROL., vol. 105, 1989, pages 115 - 126 |
TIKKA ET AL., J. NEUROSCI., vol. 21, 2001, pages 2580 - 2588 |
TROOST ET AL., CLIN. NEUROPATHOL., vol. 8, 1989, pages 289 - 294 |
VAN DEN BOSCH ET AL., NEUROREPORT, vol. 13, 2002, pages 1067 - 1070 |
VEERASARN ET AL., RADIOTHER ONCOL., vol. 73, no. 2, November 2004 (2004-11-01), pages 179 - 85 |
WILLIAMS ET AL., AM. J. PATHOL., vol. 161, 2002, pages 575 - 585 |
ZHANG ET AL., J NEUROIMMUNOL. 2005 FEB, vol. 159, no. 1-2, 26 November 2004 (2004-11-26), pages 215 - 24 |
ZHANG ET AL., J NEUROLMMUNOLOGY, vol. 159, 2005, pages 215 - 224 |
ZIEGLER-HEITBROCK ET AL., EUR. J. IMMUNOL., vol. 23, 1993, pages 2053 - 2058 |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8067035B2 (en) | 2005-12-22 | 2011-11-29 | Neuraltus Pharmaceuticals, Inc. | Chlorite formulations, and methods of preparation and use thereof |
US8231856B2 (en) | 2005-12-22 | 2012-07-31 | Neuraltus Pharmaceuticals, Inc. | Chlorite formulations and methods of preparation and use thereof |
US8501244B2 (en) | 2005-12-22 | 2013-08-06 | Neuraltus Pharmaceuticals, Inc. | Chlorite formulations and methods of preparation and use thereof |
US9266734B2 (en) | 2005-12-22 | 2016-02-23 | Neuraltus Pharmaceuticals, Inc. | Chlorite formulations and methods of preparation and use thereof |
US9839650B2 (en) | 2005-12-22 | 2017-12-12 | Neuraltus Pharmaceuticals, Inc. | Chlorite formulations, and methods of preparation and use thereof |
FR2910811A1 (en) * | 2007-01-03 | 2008-07-04 | Ass Pour Le Dev De La Biothera | Use of riluzole for preparation of drug e.g. to reestablish immune function, to treat inflammatory diseases, infection, cancer, viral infection and their virological and immunitary symptoms, leishmaniasis, malaria or bilharziasis |
WO2008096081A2 (en) * | 2007-01-03 | 2008-08-14 | Association Pour Le Developpement De La Biotherapie Experimentale Et Appliquee (A.D.B.E.A) | Use of riluzole and derivatives thereof for producing new drugs |
WO2008096081A3 (en) * | 2007-01-03 | 2008-11-06 | Ass Pour Le Dev De La Biothera | Use of riluzole and derivatives thereof for producing new drugs |
US10822421B2 (en) | 2012-08-31 | 2020-11-03 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) |
WO2015175974A1 (en) * | 2014-05-16 | 2015-11-19 | Neuraltus Pharmaceuticals, Inc. | Methods and compositions for treatment of macrophage-related disorders |
EP3142674A4 (en) * | 2014-05-16 | 2018-01-17 | Neuraltus Pharmaceuticals, Inc. | Methods and compositions for treatment of macrophage-related disorders |
Also Published As
Publication number | Publication date |
---|---|
US7105183B2 (en) | 2006-09-12 |
AU2005213300A1 (en) | 2005-08-25 |
EP1711191A4 (en) | 2008-12-17 |
US20050181068A1 (en) | 2005-08-18 |
CA2838392A1 (en) | 2005-08-25 |
EP2574342B1 (en) | 2018-03-07 |
CN102423318B (en) | 2015-09-09 |
AU2005213300B2 (en) | 2011-06-16 |
US20170065634A1 (en) | 2017-03-09 |
CA2554511C (en) | 2016-01-19 |
CA2554511A1 (en) | 2005-08-25 |
US8029826B2 (en) | 2011-10-04 |
US9364501B2 (en) | 2016-06-14 |
US20060159775A1 (en) | 2006-07-20 |
WO2005076819A3 (en) | 2006-04-13 |
JP5797083B2 (en) | 2015-10-21 |
JP2007520554A (en) | 2007-07-26 |
JP2015205901A (en) | 2015-11-19 |
CN102423318A (en) | 2012-04-25 |
JP2012067110A (en) | 2012-04-05 |
US20120295296A1 (en) | 2012-11-22 |
CN101102781A (en) | 2008-01-09 |
EP1711191B1 (en) | 2014-03-19 |
CN101102781B (en) | 2012-06-20 |
US20110053186A1 (en) | 2011-03-03 |
EP2574342A1 (en) | 2013-04-03 |
EP1711191A2 (en) | 2006-10-18 |
CA2838392C (en) | 2017-04-04 |
JP5072367B2 (en) | 2012-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9364501B2 (en) | Chlorite in the treatment of neurodegenerative disease | |
Zhang et al. | Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS) | |
Holmgren et al. | Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP‐met30) | |
Campus et al. | Diabetes and periodontal disease: A case‐control study | |
AU2014203207B2 (en) | Chlorite in the treatment of neurodegenerative disease | |
US20170106017A1 (en) | Methods and compositions for treatment of macrophage-related disorders | |
Hartard et al. | Wilson's disease with cerebral manifestation: monitoring therapy by CSF copper concentration | |
US20190298708A1 (en) | Methods of treating subjects with an elevated neurofilament light chain level | |
Dore et al. | Prospective analysis of seizures occurring in human immunodeficiency virus type-1 infection | |
Golden | Tourette syndrome: Recent advances | |
DE69732114T2 (en) | METHOD FOR DETECTING AUTOIMMUNE DISEASES | |
Moore et al. | Chromosome studies in 10 patients with the Rett syndrome | |
Haupt et al. | Severity of symptoms and rate of progression in Alzheimer's disease: a comparison of cases with early and late onset | |
Marshall et al. | Lack of cerebrospinal fluid myelin basic protein in HIV‐infected asymptomatic individuals with intrathecal synthesis of IgG | |
Widjaja et al. | Case report: generalized myasthenia gravis | |
Adunsky et al. | Basal and activated intracellular calcium ion concentrations in mononuclear cells of Alzheimer's disease and unipolar depression | |
Dijkstra | Asymptomatic neurosyphilis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005213300 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2554511 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005722556 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580003723.6 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006552151 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005213300 Country of ref document: AU Date of ref document: 20050125 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005213300 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3180/CHENP/2006 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005722556 Country of ref document: EP |